Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 3 | 1 |
List of Figures | 3 | 2 |
Executive Summary | 5 | 1 |
Market Landscape Poised for Entry of Novel Products | 5 | 1 |
Moderately-Sized but Strong First-in-Class Pipeline | 5 | 1 |
Strong Uptake of First-in-Class Products in Strategic Consolidations | 5 | 1 |
The Case for Innovation | 6 | 3 |
Growing Opportunities for Biologic Products | 7 | 1 |
Diversification of Molecular Targets | 7 | 1 |
Innovative First-in-Class Product Development Remains Attractive | 7 | 1 |
Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation | 8 | 1 |
Sustained Innovation | 8 | 1 |
Clinical and Commercial Landscape | 9 | 13 |
Therapy Area Overview | 9 | 1 |
Glaucoma | 9 | 1 |
Age-related Macular Degeneration | 9 | 1 |
Diabetic Macular Edema | 9 | 1 |
Diabetic Retinopathy | 9 | 1 |
Dry Eye Syndrome | 10 | 1 |
Disease Symptoms | 10 | 2 |
Epidemiology and Etiology | 12 | 1 |
Glaucoma | 12 | 1 |
Age-related Macular Degeneration | 12 | 1 |
Diabetic Retinopathy and Diabetic Macular Edema | 12 | 1 |
Dry Eye Syndrome | 12 | 1 |
Diagnosis | 13 | 1 |
Pathophysiology | 13 | 1 |
Healthy Eye Physiology | 13 | 1 |
Glaucoma | 14 | 1 |
Age-related Macular Edema | 15 | 1 |
Diabetic Macular Edema and Diabetic Retinopathy | 16 | 1 |
Treatment Options | 17 | 2 |
Prognosis | 19 | 1 |
Glaucoma | 19 | 1 |
Age-Related Macular Degeneration | 19 | 1 |
Diabetic Retinopathy and Diabetic Macular Edema | 19 | 1 |
Dry Eye Syndrome | 20 | 1 |
Overview of Marketed Products in Ophthalmology | 20 | 1 |
Molecule Type and Target Analysis | 20 | 2 |
Assessment of Pipeline Product Innovation | 22 | 13 |
Ophthalmology Pipeline by Molecular Target | 25 | 3 |
Comparative Distribution of Programs between the Ophthalmology Market and Pipeline by Therapeutic Target Family | 28 | 1 |
First-in-Class Pipeline Programs Targeting Novel Molecular Targets | 28 | 7 |
Signaling Network, Disease Causation and Innovation Alignment | 35 | 4 |
Complexity of Signaling Networks in Ophthalmology | 35 | 1 |
First-in-Class Matrix Assessment | 35 | 4 |
First-in-Class Target Evaluation | 39 | 11 |
Pipeline Programs Targeting RPE65 and RBP4 | 39 | 2 |
Pipeline Programs Targeting Eotaxin-1 and CCR3 | 41 | 2 |
Pipeline Programs Targeting LRP6 | 43 | 1 |
Pipeline Programs Targeting TGF-Beta 2 | 44 | 1 |
Pipeline Programs Targeting NGF, and LNGFR and TrkA Nerve Growth Factor Receptors | 45 | 3 |
Pipeline Programs Targeting Serine Protease HtrA1 | 48 | 1 |
Conclusion | 49 | 1 |
Deals and Strategic Consolidations | 50 | 13 |
Industry-Wide First-in-Class Deals | 50 | 1 |
Licensing Deals | 51 | 2 |
Licensing Deals by Molecule Type | 53 | 1 |
Licensing Deals by Molecular Target | 53 | 2 |
Licensing Deals Valued Above $100m | 55 | 1 |
Co-development Deals | 56 | 1 |
Co-development Deals by Molecule Type | 57 | 1 |
Co-development Deals by Molecular Target | 57 | 2 |
Co-development Deals Valued Above $100m | 59 | 1 |
First-in-Class Programs Not Involved in Licensing or Co-development Deals | 60 | 3 |
Appendix | 63 | 8 |
Abbreviations | 63 | 1 |
References | 63 | 5 |
Research Methodology | 68 | 1 |
Secondary Research | 69 | 2 |
Market Analysis | 69 | 1 |
Pipeline Analysis | 69 | 1 |
Overall Pipeline | 69 | 1 |
First-in-Class Analysis | 69 | 1 |
First-in-Class Matrix Assessment | 69 | 1 |
First-in-Class Target Profiles | 70 | 1 |
Licensing and Co-development Deals | 70 | 1 |
Contact Us | 70 | 1 |
Disclaimer | 70 | 1 |